drugset / Trial / NCT04115306
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and tolerability of PMD-026 in patients with metastatic breast cancer. PMD-026 is a targeted oral agent designed to kill tumor cells in metastatic breast cancer.
Timeline
- Start
- 2019-11-14
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PMD-026 | Unknown | — | Oral |
| Background | Fulvestrant | Small molecule | — | — |